Evidence map›Paper›PMID 32868878›Full record

ArticleNature medicine2020

Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo.

Colby R Maldini, Daniel T Claiborne, Ken Okawa, Tao Chen, Derrick L Dopkin, Xiaochuan Shan, Karen A Power, Radiana T Trifonova, Katharine Krupp, Meredith Phelps and 8 more

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04863066 (A Phase I Trial Using Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection), which is not on this map. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
5.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04863066 phase1unknown statusnot on this mapstarted 2021, after this paper: background citation

A Phase I Trial Using Third-Generation CAR-T-cell Therapy in Individuals With HIV-1 Infection

TypeinterventionalSponsorBeijing 302 HospitalRan2021 to 2022Enrolled8ConditionsHIV-1ArmsCAR-T cells
3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 123 citations in OpenAlex.

  1. Beyond Oncology: Exploring the Expanding Role of CAR T Cell Therapy in Autoimmune and Infectious Diseases-A Systematic Review.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Searching for a HIV-1 Cure.Theranostics · 2026
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Optimal pairing of binder and co-stimulatory domains improves dual CART cell efficacy.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Engineering of CD8mBio · 2025
    Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 1 country.

Colby R Maldini *Department of Microbiology, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Daniel T Claiborne *Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Ken OkawaRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Tao ChenRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Derrick L DopkinDepartment of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Xiaochuan ShanDepartment of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Karen A PowerRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Radiana T TrifonovaRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-6191-1970
Katharine KruppRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Meredith PhelpsRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-3522-4226
Vladimir D VrbanacRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Serah TannoRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
Timothy BatesonRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
George J LeslieDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
James A HoxieDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Christian L BoutwellRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.
James L Riley *Department of Microbiology, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. rileyj@upenn.edu.ORCID http://orcid.org/0000-0002-1057-576X
Todd M Allen *Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. tallen2@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-6609-1318
Ragon Institute of MGH, MIT and Harvard · USUniversity of Pennsylvania · USParker Institute for Cancer Immunotherapy · US

Funding

Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI DAVID S METZGER · 1999 to 2026
$78.6M
BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination ImmunotherapyUM1AI164570 · NIAID · WISTAR INSTITUTE · PI Luis J Montaner, James L. Riley · 2021 to 2026
$34.7M
First-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5M
Modeling HIV CAR-T cell trafficking and persistence in Non-Human PrimatesU19AI149680 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI RILEY, JAMES L. · 2020 to 2024
$13.2M
Sequencing and Viral Evolution CoreU19AI117950 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI WHERRY, E. JOHN · 2015 to 2019
$12.0M
Preclinical development of gene-edited human hematopoietic stem cellsU19HL129903 · NHLBI · HARVARD UNIVERSITY · PI NOVAK, RODGER · 2015 to 2019
$11.5M
TRAINING IN HIV PATHOGENESIST32AI007632 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Frederic D Bushman, James L. Riley · 2000 to 2026
$10.6M
Interrogating mechanisms of HIV pathogenesis in the humanized BLT mouse modelF32AI136750 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI CLAIBORNE, DANIEL THOMAS · 2018 to 2020
$198k
NHLBI NIH HHS U19 HL129903NIAID NIH HHS F32 AI136750NIAID NIH HHS P30 AI045008NIAID NIH HHS T32 AI007632NIAID NIH HHS U19 AI117950NIAID NIH HHS U19 AI149680NIAID NIH HHS UM1 AI126620NIAID NIH HHS UM1 AI164570
6 · The paper itself

Abstract

An effective strategy to cure HIV will likely require a potent and sustained antiviral T cell response. Here we explored the utility of chimeric antigen receptor (CAR) T cells, expressing the CD4 ectodomain to confer specificity for the HIV envelope, to mitigate HIV-induced pathogenesis in bone marrow, liver, thymus (BLT) humanized mice. CAR T cells expressing the 4-1BB/CD3-ζ endodomain were insufficient to prevent viral rebound and CD4

Indexed as

Immunotherapy, AdoptiveAnimalsAntibodies, Monoclonal, HumanizedBone MarrowCD3 ComplexCD4 AntigensGene Expression RegulationHIV-1HIV Envelope Protein gp41HIV InfectionsHumansLiverMicePeptide FragmentsProtein DomainsReceptors, Chimeric AntigenAntibodies, Monoclonal, HumanizedCD3 antigen, zeta chainCD3 ComplexCD4 AntigensCXCR4 protein, mouseHIV Envelope Protein gp41peptide C34Peptide FragmentsReceptors, Chimeric AntigenReceptors, CXCR4Tumor Necrosis Factor Receptor Superfamily, Member 9

Identifiers

PMID32868878
PMCPMC9422086
OpenAlexW3081862669

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.